36,286 Shares in Guardant Health, Inc. $GH Acquired by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,286 shares of the company’s stock, valued at approximately $5,444,000.

Several other large investors also recently modified their holdings of the company. ABS Investment Management LLC acquired a new position in Guardant Health in the second quarter valued at $345,069,000. TrinityBridge Ltd acquired a new stake in Guardant Health during the 2nd quarter worth about $45,000. Elyxium Wealth LLC bought a new position in shares of Guardant Health in the 4th quarter worth about $35,000. Parallel Advisors LLC raised its position in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in shares of Guardant Health in the 2nd quarter worth about $59,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Trading Down 0.8%

Shares of GH stock opened at $163.06 on Thursday. The firm has a market capitalization of $21.88 billion, a PE ratio of -46.72 and a beta of 1.57. The firm has a fifty day simple moving average of $159.29 and a two-hundred day simple moving average of $122.07. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same period last year, the company earned ($0.44) earnings per share. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. On average, equities analysts predict that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. UBS Group set a $150.00 target price on Guardant Health in a research report on Wednesday, June 24th. Wolfe Research initiated coverage on Guardant Health in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. Bank of America increased their price target on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Tuesday, August 25th. Finally, Evercore reiterated an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $183.78.

Insiders Place Their Bets

In related news, Director Medina Manuel Hidalgo sold 1,700 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total transaction of $279,208.00. Following the sale, the director directly owned 4,556 shares in the company, valued at approximately $748,277.44. This represents a 27.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 46,300 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the sale, the insider owned 22,979 shares in the company, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 529,024 shares of company stock valued at $80,000,525. Company insiders own 5.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.